$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416117776 Filed on August 09, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$157.0K	$391.0K
YoY Change	-59.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.470M	$9.810M
YoY Change	-34.05%	152.84%
% of Gross Profit
Research & Development	$8.713M	$27.80M
YoY Change	-68.66%	29.0%
% of Gross Profit
Depreciation & Amortization	$67.00K	$12.00K
YoY Change	458.33%	20.0%
% of Gross Profit
Operating Expenses	$8.713M	$27.80M
YoY Change	-68.66%	29.0%
Operating Profit	-$15.02M	-$38.85M
YoY Change	-61.33%	52.81%
Interest Expense	$729.0K	$1.636M
YoY Change	-55.44%	4857.58%
% of Operating Profit
Other Income/Expense, Net		-$27.99M
YoY Change		6290.64%
Pretax Income	-$14.18M	-$66.85M
YoY Change	-78.79%	158.41%
Income Tax
% Of Pretax Income
Net Earnings	-$14.18M	-$66.85M
YoY Change	-78.79%	158.44%
Net Earnings / Revenue	-9028.66%	-17095.91%
Basic Earnings Per Share		-$0.88
Diluted Earnings Per Share	-$136.6K	-$0.88
COMMON SHARES
Basic Shares Outstanding		76.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.140M	$19.20M
YoY Change	-88.85%	116.95%
Cash & Equivalents	$2.140M	$19.20M
Short-Term Investments
Other Short-Term Assets	$2.350M	$2.000M
YoY Change	17.5%	-44.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.500M	$21.20M
YoY Change	-78.77%	70.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.89M	$42.00M
YoY Change	11.65%	54444.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$220.0K	$1.050M
YoY Change	-79.05%	1809.09%
Total Long-Term Assets	$47.11M	$43.05M
YoY Change	9.44%	32511.36%
TOTAL ASSETS
Total Short-Term Assets	$4.500M	$21.20M
Total Long-Term Assets	$47.11M	$43.05M
Total Assets	$51.61M	$64.25M
YoY Change	-19.67%	410.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.89M	$11.07M
YoY Change	79.64%	16.02%
Accrued Expenses	$1.340M	$1.188M
YoY Change	12.79%	81.37%
Deferred Revenue
YoY Change
Short-Term Debt	$930.0K	$930.0K
YoY Change	0.0%	0.0%
Long-Term Debt Due	$10.52M	$240.0K
YoY Change	4283.33%	0.0%
Total Short-Term Liabilities	$59.90M	$116.5M
YoY Change	-48.6%	174.56%
LONG-TERM LIABILITIES
Long-Term Debt	$10.68M	$23.72M
YoY Change	-54.97%
Other Long-Term Liabilities		$149.0K
YoY Change
Total Long-Term Liabilities	$10.68M	$23.87M
YoY Change	-55.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.90M	$116.5M
Total Long-Term Liabilities	$10.68M	$23.87M
Total Liabilities	$70.58M	$140.4M
YoY Change	-49.74%	230.79%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$557.2M
YoY Change		30.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$18.97M	-$76.17M
YoY Change
Total Liabilities & Shareholders Equity	$51.61M	$64.25M
YoY Change	-19.67%	410.88%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$14.18M	-$66.85M
YoY Change	-78.79%	158.44%
Depreciation, Depletion And Amortization	$67.00K	$12.00K
YoY Change	458.33%	20.0%
Cash From Operating Activities	-$14.20M	-$27.10M
YoY Change	-47.6%	59.98%
INVESTING ACTIVITIES
Capital Expenditures	-$1.620M	-$890.0K
YoY Change	82.02%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$1.620M	-$890.0K
YoY Change	82.02%	-73.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.900M	43.20M
YoY Change	-90.97%	154.42%
NET CHANGE
Cash From Operating Activities	-14.20M	-27.10M
Cash From Investing Activities	-1.620M	-890.0K
Cash From Financing Activities	3.900M	43.20M
Net Change In Cash	-11.92M	15.21M
YoY Change	-178.37%	-551.34%
FREE CASH FLOW
Cash From Operating Activities	-$14.20M	-$27.10M
Capital Expenditures	-$1.620M	-$890.0K
Free Cash Flow	-$12.58M	-$26.21M
YoY Change	-52.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Expense InterestExpense	1447000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-113278000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	585000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	32895000	USD
CY2016Q2	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
	dei	Document Type DocumentType	10-Q
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3787000	USD
CY2016Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	301000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	591000	USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	10480000	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	393000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	585000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	393000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47424000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22153000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14846000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10742000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	62270000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61685000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32502000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-48852000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20281000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-312000	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	391000	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	157000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	391000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	157000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27799000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8713000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11446000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6467000	USD
CY2015Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	39245000	USD
CY2016Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15180000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-38854000	USD
CY2016Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3930000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15023000	USD
CY2015Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-25694000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	1636000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	729000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-66845000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-14175000	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-661000	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-2353000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-604000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1037000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-112674000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19244000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-672000	USD
CY2016Q1	nwbo	Class Of Warrant Or Right Granted In Registerd Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightGrantedInRegisterdDirectOfferingWeightedAverageExercisePrice	3.04
CY2016Q1	nwbo	Procees From Sale Of Availiable Securities Gross ProceesFromSaleOfAvailiableSecuritiesGross	10000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47760000	shares
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-537000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66173000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13638000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1037000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	756000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	8203000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10000000	USD
	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-337000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2211000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	628000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-1529000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	2121000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-44684000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31801000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2015000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	4303000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2015000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4028000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	15784000	USD
	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	2277000	USD
	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	4997000	USD
	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	138000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13390000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19202000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	717000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	431000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3389000	USD
	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-49000	USD
	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	254000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6792000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4235000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19670000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5812000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	275000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	10000000	USD
	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	40000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	756000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	nwbo	Redeemable Security Settlement RedeemableSecuritySettlement	0	USD
	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	0	USD
	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	51000	USD
	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	0	USD
	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	521000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	257000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	13000	USD
	us-gaap	Interest Paid Net InterestPaidNet	803000	USD
CY2016Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2100000	USD
CY2016Q2	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	55400000	USD
CY2016Q2	nwbo	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties	7600000	USD
CY2016Q2	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1614837	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	44444976	shares
CY2016Q2	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	2.67
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q2	nwbo	Class Of Warrant Or Right Granted In Registered Direct Offering ClassOfWarrantOrRightGrantedInRegisteredDirectOffering	2426470	shares
CY2016Q2	nwbo	Class Of Warrant Or Right Granted In Registerd Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightGrantedInRegisterdDirectOfferingWeightedAverageExercisePrice	1.02
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27267441	shares
CY2016Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	16791	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	42715146	shares
CY2015Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.4
CY2016Q1	nwbo	Class Of Warrant Or Right Granted In Registered Direct Offering ClassOfWarrantOrRightGrantedInRegisteredDirectOffering	12058825	shares
CY2016Q2	us-gaap	Notes Payable NotesPayable	1119000	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	1119000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	296000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216000	USD
	us-gaap	Depreciation Depreciation	80000	USD
	us-gaap	Depreciation Depreciation	15000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	NWBO
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113742204	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 40.7pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	11000	USD
CY2016Q2	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2015Q4	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	106167204	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	106167204	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95858087	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95858087	shares
CY2016Q2	us-gaap	Depreciation Depreciation	67000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	12000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47188000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46373000	USD
	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	4235000	USD
	nwbo	Adjustments To Additional Paid In Capital Modification On Warrant Exercise Price AdjustmentsToAdditionalPaidInCapitalModificationOnWarrantExercisePrice	2640000	USD
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2640000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	12000	USD
	nwbo	Adjustments To Additional Paid In Capitaloffering Cost Related To Warrants Exercise AdjustmentsToAdditionalPaidInCapitalofferingCostRelatedToWarrantsExercise	-341000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	62000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	341000	USD
	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	0	USD
CY2016Q2	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	2600000	USD
CY2016Q1	nwbo	Number Of Warrants Granted To Cognate NumberOfWarrantsGrantedToCognate	3405671	shares
CY2016Q1	nwbo	Class Of Warrants Or Rights Granted To Congnate Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedToCongnateWeightedAverageExercisePrice	1.70
CY2016Q2	nwbo	Number Of Warrants Granted To Cognate NumberOfWarrantsGrantedToCognate	5329961	shares
CY2016Q2	nwbo	Class Of Warrants Or Rights Granted To Congnate Weighted Average Exercise Price ClassOfWarrantsOrRightsGrantedToCongnateWeightedAverageExercisePrice	0.96
CY2016Q2	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	4411764	shares
CY2016Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	135000	USD
CY2015Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	135000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	58000	USD
	nwbo	Tax Receivable Related To Uk Facility TaxReceivableRelatedToUkFacility	408000	USD
	nwbo	Tax Receivable Related To Uk Facility TaxReceivableRelatedToUkFacility	0	USD
	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	0	USD
CY2016Q2	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	-2640000	USD
CY2015Q2	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	0	USD
	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	-2640000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16815000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66845000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22921000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-113278000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103831000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75619000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	100782000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72530000	shares
CY2016Q2	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	8.82
CY2016Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	11.86
CY2016Q2	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.96
	nwbo	Common Stock Shares And Warrants Issued Favored Nation Provision Terms CommonStockSharesAndWarrantsIssuedFavoredNationProvisionTerms	During the period ended June 30, 2016 the Company entered into two financings with unrelated institutional investors that triggered the most favored nation provision. The first reset in the period ended March 31, 2016 had an effective price of $1.70 and would result in an obligation by the Company to issue 6.0 million shares to Cognate. The second reset occurred in the three month period ended June 30, 2016 had an effective price of $0.96 that resulted in an obligation to issue an additional 12.0 million shares. In total, the Company has an obligation to issue 18 million shares to Cognate as of June 30, 2016 under the most favored nation provision.

Files In Submission

Name	View Source	Status
0001144204-16-117776-index-headers.html	Edgar Link	pending
0001144204-16-117776-index.html	Edgar Link	pending
0001144204-16-117776.txt	Edgar Link	pending
0001144204-16-117776-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nwbo-20160630.xml	Edgar Link	completed
nwbo-20160630.xsd	Edgar Link	pending
nwbo-20160630_cal.xml	Edgar Link	unprocessable
nwbo-20160630_def.xml	Edgar Link	unprocessable
nwbo-20160630_lab.xml	Edgar Link	unprocessable
nwbo-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v445783_10q.htm	Edgar Link	pending
v445783_ex31-1.htm	Edgar Link	pending
v445783_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2016 Q2 Form 10-Q Financial Statement

#000114420416117776 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2016 Q2 Form 10-Q Financial Statement

#000114420416117776 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo